西妥昔单抗联合或不联合非克拉妥珠单抗在泛难治性复发/转移性头颈癌中的随机II期试验
这项多中心随机非比较II期研究评估了非克拉妥珠单抗联合或不联合西妥昔单抗在复发/转移性头颈鳞癌中的疗效。联合组达到预设显著性标准,中位无进展生存期3.7个月(90%CI下限2.3个月,P=0.04),客观缓解率19%。单药组因无效提前关闭。
要点
- 联合组中位无进展生存期3.7个月,90%CI下限2.3个月,P=0.04,达到显著性标准
- 联合组客观缓解率19%(6/32),含2例完全缓解和4例部分缓解
- 探索性分析中HPV阴性亚组联合治疗客观缓解率38%(6/16),HPV阳性亚组0%(0/16),P=0.02
核心结论
- 非克拉妥珠单抗联合西妥昔单抗组达到无进展生存期显著性标准,值得开展III期研究。
- HPV阴性头颈鳞癌可考虑作为选择标准。
研究设计与样本
- 多中心、随机、非比较性II期研究,评估非克拉妥珠单抗联合或不联合西妥昔单抗治疗复发/转移性头颈鳞癌。
- 2018年至2020年随机分配60例患者,58例接受治疗;单药组27例,联合组33例。
- 主要终点为中位无进展生存期,若90%CI下限排除历史对照的2个月则达到显著性标准。
- 关键入组标准:已知HPV状态、西妥昔单抗耐药(根治性或复发/转移阶段暴露后6个月内进展)、铂类和抗PD-1单抗耐药。
- 采用连续贝叶斯无效性监测。
主要发现
- 单药组因无效提前关闭。
- 联合组中位无进展生存期3.7个月(90%CI下限2.3个月;P=0.04),达到预设显著性标准。
- 联合组客观缓解率19%(6/32),包括2例完全缓解和4例部分缓解。
- 探索性分析仅限联合组:HPV阳性 vs HPV阴性亚组的中位无进展生存期2.3 vs 4.1个月(P=0.03),客观缓解率0%(0/16) vs 38%(6/16;P=0.02)。
- cMet过表达与HPV阴性疾病进展风险降低相关,但与HPV阳性疾病无关(交互作用P=0.02)。
关键数值与推荐
- 联合组达到主要终点显著性标准:中位无进展生存期3.7个月,90%CI下限2.3个月,P=0.04。
- 联合组客观缓解率19%(6/32)。
- HPV阳性 vs HPV阴性亚组:中位无进展生存期2.3 vs 4.1个月(P=0.03);客观缓解率0%(0/16) vs 38%(6/16;P=0.02)。
- cMet过表达与进展风险降低的关联在HPV阴性但非HPV阳性疾病中显著(交互作用P=0.02)。
临床怎么用
- 作者认为联合组达到无进展生存期显著性标准,值得开展III期研究。
- 作者提出HPV阴性头颈鳞癌可考虑作为选择标准。
局限性
- 单药组因无效提前关闭。
- 探索性分析仅限联合组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Primary or acquired resistance to cetuximab, an antiepidermal growth factor receptor monoclonal antibody (mAb), minimizes its utility in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Aberrant hepatocyte growth factor/cMet pathway activation is an established resistance mechanism. Dual pathway targeting may overcome resistance. PATIENTS AND METHODS: This multicenter, randomized, noncomparative phase II study evaluated ficlatuzumab, an antihepatocyte growth factor mAb, with or without cetuximab in recurrent/metastatic HNSCC. The primary end point was median progression-free survival (PFS); an arm met significance criteria if the lower bound of the 90% CI excluded the historical control of 2 months. Key eligibility criteria were HNSCC with known human papillomavirus (HPV) status, cetuximab resistance (progression within 6 months of exposure in the definitive or recurrent/metastatic setting), and resistance to platinum and anti-PD-1 mAb. Secondary end points included objective response rate (ORR), toxicity, and the association of HPV status and cMet overexpression with efficacy. Continuous Bayesian futility monitoring was used. RESULTS: From 2018 to 2020, 60 patients were randomly assigned and 58 were treated. Twenty-seven versus 33 patients were allocated to monotherapy versus combination. Arms were balanced for major prognostic factors. The monotherapy arm closed early for futility. The combination arm met prespecified significance criteria with a median PFS of 3.7 months (lower bound 90% CI, 2.3 months; P = .04); the ORR was 6 of 32 (19%), including two complete and four partial responses. Exploratory analyses were limited to the combination arm: the median PFS was 2.3 versus 4.1 months (P = .03) and the ORR was 0 of 16 (0%) versus 6 of 16 (38%; P = .02) in the HPV-positive versus HPV-negative subgroups, respectively. cMet overexpression was associated with reduced hazard of progression in HPV-negative but not HPV-positive disease (P interaction = .02). CONCLUSION: The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion.
引用
- Bauman JE, Saba NF, Roe D, et al. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol. 2023. PMID: 36977289. doi:10.1200/JCO.22.01994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。